Journal of Inflammatory Diseases
The Official Journal of Qazvin University of Medical Sciences
RNA based antisense drugs: different types, molecular mechanisms and clinical trials
Abstract
A few decades ago, drugs which were used to treat different diseases were only limited to chemical drugs, peptides, monoclonal antibodies and recombinant proteins. Since the first nucleotide drug was approved by the Food and Drug Organization of the United States, this new generation of medications became remarkable to researchers and pharmacists . Ribonucleic acid ( RNA) based drugs were among these category that encountered a number of hurdles along the way such as potential immunogenicity, structural instability and the need for a vehicle to deliver the drug into the cell . With regards to the simplicity of the RNA therapeutics design, researchers could overcome the challenges with improvements in synthetic delivery carriers and chemical modifications of the RNA therapeutics. Numerous types of RNA-based drugs are being extensively tested in various stages of clinical trials. This review focuses on therapeutic ribozymes, antisense oligonucleotides, interfering RNAs and aptamers.
Copyright
© 2024, Journal of Inflammatory Diseases. This open-access article is available under the Creative Commons Attribution-NonCommercial 4.0 (CC BY-NC 4.0) International License (https://creativecommons.org/licenses/by-nc/4.0/), which allows for the copying and redistribution of the material only for noncommercial purposes, provided that the original work is properly cited.
Similar Articles
Aptamer-Assisted Delivery of Nucleotides with Tumor-Suppressing Properties for Targeted Cancer Therapies
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Aptamer-Assisted Delivery of Nucleotides with Tumor-Suppressing Properties for Targeted Cancer Therapies. J Adv Immunopharmacol. 2021;1(4):e114909. doi: https://doi.org/10.5812/tms.114909
Flexible Aptamer-Based Nucleolin-Targeting Cancer Treatment Modalities: A Focus on Immunotherapy, Radiotherapy, and Phototherapy
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Flexible Aptamer-Based Nucleolin-Targeting Cancer Treatment Modalities: A Focus on Immunotherapy, Radiotherapy, and Phototherapy. J Adv Immunopharmacol. 2021;1(3):e113991. doi: https://doi.org/10.5812/tms.113991
Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design
Shatizadeh Malekshahi S, Arefian E, Salimi V, Mokhtari Azad T, Yavarian J. Potential siRNA Molecules for Nucleoprotein and M2/L Overlapping Region of Respiratory Syncytial Virus: In Silico Design. Jundishapur J Microbiol. 2016;9(4):e60047. doi: https://doi.org/10.5812/jjm.34304
Chemotherapeutic, Toxin, and Therapeutic Protein Delivery via Nucleolin Aptamer-functionalized Nanoplatforms for Targeted Cancer Therapy
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Chemotherapeutic, Toxin, and Therapeutic Protein Delivery via Nucleolin Aptamer-functionalized Nanoplatforms for Targeted Cancer Therapy. J Adv Immunopharmacol. 2021;1(1):e113773. doi: https://doi.org/10.5812/tms.113773
Nanocarriers Usage for Drug Delivery in Cancer Therapy
Khodabandehloo H, Zahednasab H, Ashrafi Hafez A. Nanocarriers Usage for Drug Delivery in Cancer Therapy. Int J Cancer Manag. 2016;9(2):e3966. doi: https://doi.org/10.17795/ijcp-3966
- Scopus by DOI: 0
Last Update: 6 days ago
- Scopus by Title: 0
Last Update: 6 days ago
- Scopus by Title (Ref): 0
Last Update: 6 days ago
- CrossRef: 0
Last Update: 5 days ago
Ordering Reprints
Articles are published under the Creative Commons license stated on each article. No permission or royalty fee is required for uses permitted by that license. CCC handles optional bulk and customized reprint orders. Any quotation covers production and delivery services only, not copyright permission. > Request Reprints from CCC